Lean Mass Changes With Semaglutide in Adults With Type 1 Diabetes and Overweight/Obesity. | MicrobiomeTrials← Back to trialsNCT07891156
Lean Mass Changes With Semaglutide in Adults With Type 1 Diabetes and Overweight/Obesity.
RecruitingPHASE2, PHASE3INTERVENTIONAL
Trial Details
Start: 2026-10-13Est. Completion: 2028-09-01
Enrollment target: 40 participants Locations- Research Institute of the McGill University Health Centre Royal Victoria Hospital, Montreal, Quebec, Canada
Other microbiome trials you might be interested in
Type 1 Diabetes MellitusType 2 Diabetes Mellitus
This is an open label, two-arm, randomized multi-center clinical device study in adult subjects with Type 1 diabetes (T1…
Gdansk, PolandEst. completion Nov 15, 2026
Nephrotic SyndromeLipodystrophyMetabolic SyndromeHealthy VolunteerDiabetesMetabolic Associated Steatotic Liver Disease
Background:
Abnormal fats in the blood can lead to many problems, including heart disease. Researchers want to learn mo…
Bethesda, United StatesEst. completion Feb 1, 2030
Overweight and Obesity
The purpose of this study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of ascending dose…
Phoenix, United StatesEst. completion Dec 2027